3164 — Genmont Biotech Balance Sheet
0.000.00%
- TWD1.57bn
- TWD1.41bn
- TWD385.37m
- 67
- 41
- 16
- 33
Annual balance sheet for Genmont Biotech, fiscal year end - December 31st, TWD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Cash | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | 465 | 422 | 401 | 328 | 426 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 46.4 | 55.1 | 51.8 | 40 | 33.3 |
| Total Inventory | |||||
| Prepaid Expenses | |||||
| Total Current Assets | 596 | 581 | 522 | 466 | 542 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 954 | 1,059 | 1,113 | 1,060 | 1,037 |
| Net Intangible Assets | |||||
| Long Term Investments | |||||
| Other Long Term Assets | |||||
| Total Assets | 1,613 | 1,698 | 1,696 | 1,653 | 1,709 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 95 | 139 | 161 | 146 | 140 |
| Long Term Debt | |||||
| Capital Lease Obligations | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Deferred Income Tax | |||||
| Minority Interest | |||||
| Total Other Liabilities | |||||
| Total Funded Status | |||||
| Total Liabilities | 284 | 322 | 344 | 337 | 357 |
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Treasury Stock | |||||
| Other Equity | |||||
| Total Equity | 1,329 | 1,376 | 1,351 | 1,316 | 1,352 |
| Total Liabilities & Shareholders' Equity | 1,613 | 1,698 | 1,696 | 1,653 | 1,709 |
| Total Common Shares Outstanding |